Chiauranib

Generic Name: Chiauranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₁N_₃O_₃

CAS Number: 1256349-48-0

Unique Ingredient Identifier: F40IRN5981

Background: Chiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).

Indication: 用于治疗经过2线系统化疗方案后疾病进展或复发的小细胞肺癌（SCLC）。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Chiauranib
Drug: Albumin-paclitaxel Injection
Drug: Gemcitabine Injection

First Posted Date: 2024-07-09

Last Posted Date: 2024-07-09

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 42

Registration Number: NCT06492915

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Phase 2

Active, not recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Chiauranib

First Posted Date: 2022-08-11

Last Posted Date: 2024-07-16

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 40

Registration Number: NCT05497843

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Mass Balance Study of [14C]Chiauranib

Not Applicable

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Chiauranib

First Posted Date: 2022-05-12

Last Posted Date: 2024-07-15

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 6

Registration Number: NCT05371899

Locations: 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China

Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Chiauranib

First Posted Date: 2022-04-26

Last Posted Date: 2023-02-09

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 16

Registration Number: NCT05346601

Locations: 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Phase 2

Terminated

Conditions: Triple-negative Breast Cancer

Interventions: Drug: Chiauranib
Drug: capecitabine

First Posted Date: 2022-04-20

Last Posted Date: 2024-11-19

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 9

Registration Number: NCT05336721

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China

and more 1 locations

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Phase 1

Recruiting

Conditions: Small Cell Lung Cancer
Advanced Solid Malignant Tumor

Interventions: Drug: Chiauranib

First Posted Date: 2022-03-09

Last Posted Date: 2024-07-16

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 36

Registration Number: NCT05271292

Locations: 🇺🇸
Dana Farber Cancer Institue, Boston, Massachusetts, United States
🇺🇸
Providence/St. Joe Cancer Institute/Crosson Cancer Institute, Fullerton, California, United States
🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States

and more 8 locations

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Phase 3

Recruiting

Conditions: Paclitaxel
Chiauranib
Ovarian Cancer
Relapsed or Refractory

Interventions: Drug: Placebo
Drug: chiauranib
Drug: Paclitaxel

First Posted Date: 2021-06-10

Last Posted Date: 2024-10-18

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 454

Registration Number: NCT04921527

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

Phase 3

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Chiauranib

First Posted Date: 2021-04-05

Last Posted Date: 2024-12-09

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 184

Registration Number: NCT04830813

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-hodgkin's Lymphoma

Interventions: Drug: Chiauranib
Drug: Chidamide

First Posted Date: 2019-06-04

Last Posted Date: 2022-03-09

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 9

Registration Number: NCT03974243

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: chiauranib
Drug: etoposide
Drug: paclitaxel

First Posted Date: 2019-04-03

Last Posted Date: 2021-03-19

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 47

Registration Number: NCT03901118

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy